The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

被引：14
|
作者：
Grinshpun, Albert [1 ,2 ,3 ]
Tolaney, Sara M. M. [1 ,2 ,3 ]
Burstein, Harold J. J.
Jeselsohn, Rinath [1 ,2 ,3 ]
Mayer, Erica L. L. [1 ,2 ,3 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02215 USA
[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
NPJ BREAST CANCER | 2023年 / 9卷 / 01期
关键词：
RIBOCICLIB PLUS FULVESTRANT; MONALEESA-3; TRIAL; ABEMACICLIB PLUS; PATIENTS PTS; SURVIVAL; PALBOCICLIB; LETROZOLE; THERAPY; INTERIM; WOMEN;
D O I：
10.1038/s41523-023-00520-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences.
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [1] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    npj Breast Cancer, 9
  • [2] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    ONKOLOGE, 2016, 22 (07): : 507 - 508
  • [4] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [5] CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
    Hui, Rina
    de Boer, Richard
    Lim, Elgene
    Yeo, Belinda
    Lynch, Jodi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 3 - 14
  • [6] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [7] CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
    Fedele, Palma
    Cinieri, Saverio
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) : 1237 - 1239
  • [8] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
    Pla, Helena
    Felip, Eudald
    Obadia, Veronica
    Pernas, Sonia
    Vinas, Gemma
    Margeli, Mireia
    Fort-Culillas, Roser
    Del Barco, Sonia
    Sabate, Nuria
    Fort, Eduard
    Lezcano, Clara
    Cirauqui, Beatriz
    Quiroga, Vanesa
    Stradella, Agostina
    Gil, Miguel Gil
    Esteve, Anna
    Recalde, Sabela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
  • [9] Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
    Jeong, J. H.
    Jeong, H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2021, 32 : S72 - S73
  • [10] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Shah, Ami N.
    Lim, Bora
    Mita, Monica M.
    Mauer, Elizabeth
    Layng, Kayla V.
    Chao, Calvin
    Brufsky, Adam M.
    CANCER RESEARCH, 2023, 83 (05)
12345